Oncotelic Therapeutics Debt To Equity vs. Current Valuation
| OTLCDelisted Stock | USD 0.02 0 6.38% |
For Oncotelic Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncotelic Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncotelic Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncotelic Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncotelic Therapeutics over time as well as its relative position and ranking within its peers.
Oncotelic |
Oncotelic Therapeutics Current Valuation vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncotelic Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncotelic Therapeutics value to that of its competitors to determine the firm's financial worth. Oncotelic Therapeutics is regarded third in debt to equity category among its peers. It is regarded second in current valuation category among its peers reporting about 77,762,586 of Current Valuation per Debt To Equity. Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncotelic Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncotelic Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Oncotelic Current Valuation vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Oncotelic Therapeutics |
| = | 0.40 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Oncotelic Therapeutics |
| = | 31.34 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Oncotelic Current Valuation vs Competition
Oncotelic Therapeutics is regarded second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is now estimated at about 269.39 Million. Oncotelic Therapeutics retains roughly 31.34 Million in current valuation claiming about 12% of stocks in Biotechnology industry.
Oncotelic Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncotelic Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncotelic Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Oncotelic Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Oncotelic Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes and CA4P for the treatment of advanced metastatic melanoma. Oncotelic Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.
Oncotelic Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncotelic Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncotelic Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncotelic Therapeutics' important profitability drivers and their relationship over time.
Use Oncotelic Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncotelic Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncotelic Therapeutics will appreciate offsetting losses from the drop in the long position's value.Oncotelic Therapeutics Pair Trading
Oncotelic Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Oncotelic Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncotelic Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncotelic Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncotelic Therapeutics to buy it.
The correlation of Oncotelic Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncotelic Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncotelic Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncotelic Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncotelic Therapeutics position
In addition to having Oncotelic Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Cap ETFs Thematic Idea Now
Large Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large Cap ETFs theme has 678 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |